Enveda Starts Phase 1b of AI-Discovered Small-Molecule Anti-Inflammatory for Atopic Dermatitis
Dr. Vince Clinical Research, based in Overland Park, Kansas, specialized in early phase and multi-site clinical trials across therapeutic areas including neuroscience, infectious diseases, and cardiometabolic disorders, has announced that the first patient has been dosed in a Phase 1b trial testing Enveda’s investigational drug ENV-294 in adults with moderate to severe atopic dermatitis. The multi-site study is evaluating the candidate’s safety, tolerability, pharmacodynamics, and early efficacy.
Dr. Vince Clinical Research, based in Overland Park, Kansas, specialized in early phase and multi-site clinical trials across therapeutic areas including neuroscience, infectious diseases, and cardiometabolic disorders, has announced that the first patient has been dosed in a Phase 1b trial testing Enveda’s investigational drug ENV-294 in adults with moderate to severe atopic dermatitis. The multi-site study is evaluating the candidate’s safety, tolerability, pharmacodynamics, and early efficacy.
Dr. Vince Clinical Research is a full-service CRO specializing in early phase trials with healthy and patient volunteers. Its capabilities include clinical operations, biostatistics, PK/PD, and medical writing, supported by a global site network. The company runs a 90-bed unit in Overland Park with a cGMP pharmacy and facilities designed for recruitment and retention.
The current collaboration builds on Enveda’s recent Series D financing, which raised $150 million and brought total funding to $517 million.
ENV-294 is a small molecule discovered through Enveda’s proprietary drug discovery platform and is described as a first-in-class anti-inflammatory compound. It is intended to address atopic dermatitis, which affects more than 26 million people in the United States and around 200 million globally, according to the National Eczema Association, and other chronic inflammatory conditions through a novel mechanism of action. Enveda is positioning the candidate for patients who require systemic therapies but do not respond adequately to or cannot tolerate existing options.
Enveda’s discovery engine is built around a “chemical sequencer” that integrates metabolomics, automation, and AI. Its foundation model, PRISM, trained on more than a billion small molecule mass spectra, predicts molecular structures directly from spectra. This system supports high-throughput screening in automated laboratories, allowing the company to prioritize and develop compounds systematically. Enveda reports that this platform delivers development candidates more than four times faster and at lower cost than industry averages.
The Phase 1b study builds on results from an earlier Phase 1a trial, also conducted by Dr. Vince Clinical Research, which tested ENV-294 in healthy volunteers. That study was randomized, double-blind, placebo-controlled, and included both single and multiple ascending dose cohorts. ENV-294 was reportedly well tolerated across all doses, with no dose-limiting toxicities or serious adverse events, and showed a favorable pharmacokinetic profile.
We track updates like this weekly in Where Tech Meets Bio—our newsletter on startups, platforms, and deals at the intersection of biotech and digital.
Topic: Clinical Trials
